Cargando…
Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s Disease
BACKGROUND: Parkinson’s disease (PD) is the second most common neurodegenerative disease with a significant public health burden. It is characterized by the gradual degeneration of dopamine neurons in the central nervous system. Although symptomatic pharmacological management remains the primary the...
Autores principales: | Liu, Jia-Si, Chen, Ying, Shi, Dan-Dan, Zhang, Bao-Rong, Pu, Jia-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207905/ https://www.ncbi.nlm.nih.gov/pubmed/36582064 http://dx.doi.org/10.2174/1570159X21666221229154830 |
Ejemplares similares
-
Editorial: Emerging talents in frontiers in pharmacology: pharmacogenetics and pharmacogenomics 2022
por: Klomp, Sylvia D., et al.
Publicado: (2023) -
Association Between Dystonia-Related Genetic Loci and Parkinson's Disease in Eastern China
por: Yang, Wen-Yi, et al.
Publicado: (2022) -
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson’s Disease
por: Jing, Xiao-Zhong, et al.
Publicado: (2023) -
Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis
por: Yang, Xuerong, et al.
Publicado: (2022) -
Neuroprotective Potential and Underlying Pharmacological Mechanism of Carvacrol for Alzheimer’s and Parkinson’s Diseases
por: Javed, Hayate, et al.
Publicado: (2023)